Diab S - Search Results

1

MAP kinase-interacting kinases--emerging targets against cancer.

Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S. Diab S, et al. Chem Biol. 2014 Apr 24;21(4):441-452. doi: 10.1016/j.chembiol.2014.01.011. Epub 2014 Mar 6. Chem Biol. 2014. PMID: 24613018 Review.

2

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, Wang S. Diab S, et al. ChemMedChem. 2014 May;9(5):962-72. doi: 10.1002/cmdc.201300552. Epub 2014 Feb 12. ChemMedChem. 2014. PMID: 24677692

3

Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.

Yu M, Li P, Basnet SK, Kumarasiri M, Diab S, Teo T, Albrecht H, Wang S. Yu M, et al. Among authors: diab s. Eur J Med Chem. 2015 May 5;95:116-26. doi: 10.1016/j.ejmech.2015.03.032. Epub 2015 Mar 17. Eur J Med Chem. 2015. PMID: 25800647

4

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.

Teo T, Yang Y, Yu M, Basnet SK, Gillam T, Hou J, Schmid RM, Kumarasiri M, Diab S, Albrecht H, Sykes MJ, Wang S. Teo T, et al. Among authors: diab s. Eur J Med Chem. 2015 Oct 20;103:539-50. doi: 10.1016/j.ejmech.2015.09.008. Epub 2015 Sep 9. Eur J Med Chem. 2015. PMID: 26408454

5

Unveiling new chemical scaffolds as Mnk inhibitors.

Diab S, Li P, Basnet SK, Lu J, Yu M, Albrecht H, Milne RW, Wang S. Diab S, et al. Future Med Chem. 2016;8(3):271-85. doi: 10.4155/fmc.15.190. Epub 2016 Feb 24. Future Med Chem. 2016. PMID: 26910782

6

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Among authors: diab s. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

7

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Diab S, Abdelaziz AM, Li P, Teo T, Basnet SKC, Noll B, Rahaman MH, Lu J, Hou J, Yu M, Le BT, Albrecht H, Milne RW, Wang S. Diab S, et al. Eur J Med Chem. 2017 Oct 20;139:762-772. doi: 10.1016/j.ejmech.2017.08.006. Epub 2017 Aug 3. Eur J Med Chem. 2017. PMID: 28863357

8

Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.

Abdelaziz AM, Diab S, Islam S, Basnet SKC, Noll B, Li P, Mekonnen LB, Lu J, Albrecht H, Milne RW, Gerber C, Yu M, Wang S. Abdelaziz AM, et al. Among authors: diab s. Med Chem. 2019;15(6):602-623. doi: 10.2174/1573406415666181219111511. Med Chem. 2019. PMID: 30569866

9

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?

Diab S, Yu M, Wang S. Diab S, et al. J Med Chem. 2020 Jul 23;63(14):7458-7474. doi: 10.1021/acs.jmedchem.9b01985. Epub 2020 Mar 19. J Med Chem. 2020. PMID: 32150405 Review.

10

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Yu M, Teo T, Yang Y, Li M, Long Y, Philip S, Noll B, Heinemann GK, Diab S, Eldi P, Mekonnen L, Anshabo AT, Rahaman MH, Milne R, Hayball JD, Wang S. Yu M, et al. Among authors: diab s. Eur J Med Chem. 2021 Mar 15;214:113248. doi: 10.1016/j.ejmech.2021.113248. Epub 2021 Feb 3. Eur J Med Chem. 2021. PMID: 33571827

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

231 results

Search Page